市場調査レポート
商品コード
1264149
COVID-19市場:競合情勢、2023年COVID-19- Competitive Landscape, 2023 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
COVID-19市場:競合情勢、2023年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 800 Pages
納期: 2~10営業日
|
当レポートは、COVID-19市場について調査し、COVID-19の概要と治療薬動向、参入企業の比較評価(治療法別、開発ステージ別、技術別)などをまとめています。
DelveInsight's , "COVID-19 - Competitive landscape, 2023," report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Coronaviruses are a large family of viruses that can cause illness in animals or humans. In humans there are several known coronaviruses that cause respiratory infections. These coronaviruses range from the common cold to more severe diseases such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.
A wide range of symptoms for COVID-19 have been reported. These symptoms include:
COVID-19 can be prevented through pharmaceutical (i.e., vaccination) and non-pharmaceutical interventions (e.g., masking, physical distancing, hand hygiene). All of these preventative measures are important to protect individuals from acquiring and transmitting the SARS-CoV-2 virus and should be done in conjunction with one another.
Zydus Lifesciences Ltd. is headquartered in Ahmedabad, India, Zydus Corporate Park. The group has manufacturing sites and research facilities spread across Gujarat, Maharashtra, Goa, and Himachal Pradesh, Sikkim in India, the USA, and Brazil. The Zydus Research Centre is the dedicated research arm of the Zydus Group. With its over 400 research professionals, ZRC spearheads the group's global quest to create healthier and happier communities. Vaccine Technology Centre of Zydus Cadila has a wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate, and other subunit vaccines for unmet needs.
ZyCoV-D is India's first indigenously developed plasma DNA vaccine targeted against COVID-19. In addition, ZyCoV-D is the world's first Plasmid DNA Vaccine authorized for COVID-19 prevention. Zydus Cadila announced it had applied for Emergency Use Authorization (EUA) to the office of the DCGI for ZyCoV-D on July 1, 2021.
The ZyCoV-D vaccine was developed by Zydus Cadila using a non-replicating and non-integrating plasmid carrying the novel coronavirus gene and approved by the Drugs Controller General of India (DCGI) to conduct late-stage clinical trials. ZyCoV-D is a three-dose intradermal vaccine applied using The PharmaJet® needle-free system, Tropis®, which can significantly reduce any side effects. Also, being a plasmid DNA vaccine, ZyCoV-D doesn't display vector-based immunity concerns, says the Company. A painless, needle-free injector delivers the immunization in a narrow fluid stream into the skin.
AstraZeneca, is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
In May 2020, AstraZeneca received support of more than $1bn from BARDA for the development, production and delivery of the vaccine under an agreement with the US Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. The vaccine has been granted a conditional marketing authorization or emergency use in more than 70 countries across six continents, and with the Emergency Use Listing granted by the World Health Organization this accelerates the pathway to access in up to 142 countries through the COVAX Facility.
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
BNT162b2, is comprised of a nucleoside modified messenger RNA (modRNA) encoding an optimized viral full-length spike (S) glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The S glycoprotein is the target of virus neutralizing antibodies. On August 23, 2021, FDA announced the first approval of a COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and the approved vaccine is marketed as Comirnaty, for the prevention of COVID-19 in individuals 12 years of age and older.
Comirnaty is a monovalent COVID-19 vaccine that is approved for use as a two-dose primary series for the prevention of COVID-19 in individuals 12 years of age and older. It is also authorized for emergency use to provide a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.
Nobelpharma committed to development of critical but neglected drugs in order to fulfill social mandate. Nobelpharma have constantly been aspiring to conduct research and development of drugs that are not the prime targets for many pharmaceutical companies due to questionable economic viability with a small number of patients. Company development pipeline mainly includes the drugs such as orphan drugs that have been strongly requested by patients, academic societies, or the government, as well as off-label drugs and pediatric medicines.
Sargramostim is a man-made version of a particular natural substance made in the body. It is used to increase the production of white blood cells in the body. Sargramostim is given to people who have reduced abilities for producing white blood cells. It is also used in certain treatment procedures (such as bone marrow/stem cell transplant). It is a supportive medication but does not help in the treatment of cancer. Currently the product is in Phase II/III stage of development for the treatment of COVID-19.
Staidson is a publicly-traded pharmaceutical company headquartered in Beijing, China, focusing on drug research and development (R&D), manufacturing and sales of innovative medicines with independent intellectual property rights. The company covers early stage exploratory research, drug discovery, process development and pilot scale-up, preclinical biological evaluation, clinical development to drug production and commercialization. Staidson is an innovative biopharmaceutical enterprise with a complete biopharma industrial chain, R&D facilities, and production and marketing systems. Staidson is a listed company on the Shenzhen Stock Exchange, China and a national high-tech enterprise.
BDB-001, a monoclonal anti-C5a antibody is being developed by Staidson Beijing BioPharmaceuticals in collaboration with Beijing Defengrui Biotechnology Co. Ltd.
The drug is currently in Phase II/III stage of clinical trial evaluation to treat COVID-19 Pneumonia. It is being administered as intravenous infusion. BDB-001 specifically binds to C5a, so that C5a loses its ability to bind to its receptors, thereby blocking its biological functions, such as neutrophil chemotaxis, intracellular lysozyme release, increased levels of inflammatory factors and oxygen Respiratory bursts, while not affecting C5 cleavage and MAC formation.
NeuroActiva Inc. is a clinical stage bio-pharmaceutical company committed to the discovery and development of new drugs to prevent and treat Alzheimer's disease and Covid-19. NeuroActiva have developed patented neuroprotection and neurogenesis methods that can prevent and treat Alzheimer's disease, as well as combination therapy with anti-viral drugs to treat Covid-19.
The drug NA-831 is a small molecule drug that can be administered orally. The drug is an endogenous compound i.e. it already exists in the human brain. Basically, the drug is very safe and has no toxicity, suitable for long term treatment and prevention purpose. In November 2020, NeuroActiva initiated a Phase III randomized, double-blind, placebo-controlled, in order to evaluate the efficacy and safety of oral polio vaccine and NA-831 for prophylaxis and treatment of early onset of Covid-19. With the enrollment of 3600 participants the trial is in enrolling by invitation stage and expected to be completed by November 2022.
Established in 1997 and headquartered in Ho chi Minh City, Vietnam, Nanogen Pharmaceutical Biotechnology is a leading company that develops, manufactures and markets novel active Biopharmaceutical ingredients (APIs) based on advances in recombinant DNA and protein technologies. Nanogen offers a variety of gene-to-therapy biopharmaceuticals for the treatment of hepatitis B, hepatitis C, anemia due to chronic renal failure, oncology, etc. Its therapeutic injection products are developed, manufactured and marketed under strict compliance with current GMP and tight QC/QA procedures, and are sold in various countries in Asia, Europe, Africa and America.
Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine (SARS-CoV-2 recombinant spike protein with aluminum adjuvant). Currently the product is in Phase III stage of development for Covid-19. Nanocovax completed 120 injections of Phase I clinical trials in 60 volunteers. The research team's representative presented the results that: all 3 injection doses of 25mcg, 50mcg and 75mcg have 100% safety, 90% protection against SARS-CoV-2 virus infection and all have good immunity. Currently the product is in Phase III stage of development for the prevention of Covid-19.
The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).